| Megan M Workman, C-FNP | |
|
200 Bunker Hill Dr, Aitkin, MN 56431-1865 | |
| (218) 927-2157 | |
| Not Available |
| Full Name | Megan M Workman |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 200 Bunker Hill Dr, Aitkin, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609217223 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | (* (Not Available)) | Primary |
| Entity Name | Aitkin Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942277835 PECOS PAC ID: 4981514692 Enrollment ID: O20031107000093 |
News Archive
It may not seem like big news, but if you've followed the long-running, stubborn and mostly dug-in debate over reforming medical malpractice in the U.S., you know that when doctors and lawyers issue a joint news release, something is really going on. ... Formally, it's called "Disclosure, Apology and Offer" and it's a key provision of the new state health cost law. Massachusetts doctors and lawyers have agreed to work side by side on this less hostile (and potentially cost-saving) approach to dealing with medical errors and malpractice.
In a Huffington Post opinion piece, USAID Administrator Rajiv Shah writes about the Saving Lives at Birth: A Grand Challenge in Development competition, which "called for groundbreaking prevention and treatment approaches for pregnant mothers and newborns around the time of birth in rural settings."
The percentage of personal bankruptcies linked to medical bills or illness changed little, and the absolute number actually increased in Massachusetts after the implementation of its landmark 2006 law requiring people to buy health insurance, a Harvard study says.
Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.
Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Megan M Workman, C-FNP 200 Bunker Hill Dr, Aitkin, MN 56431-1865 Ph: (218) 927-2157 | Megan M Workman, C-FNP 200 Bunker Hill Dr, Aitkin, MN 56431-1865 Ph: (218) 927-2157 |
News Archive
It may not seem like big news, but if you've followed the long-running, stubborn and mostly dug-in debate over reforming medical malpractice in the U.S., you know that when doctors and lawyers issue a joint news release, something is really going on. ... Formally, it's called "Disclosure, Apology and Offer" and it's a key provision of the new state health cost law. Massachusetts doctors and lawyers have agreed to work side by side on this less hostile (and potentially cost-saving) approach to dealing with medical errors and malpractice.
In a Huffington Post opinion piece, USAID Administrator Rajiv Shah writes about the Saving Lives at Birth: A Grand Challenge in Development competition, which "called for groundbreaking prevention and treatment approaches for pregnant mothers and newborns around the time of birth in rural settings."
The percentage of personal bankruptcies linked to medical bills or illness changed little, and the absolute number actually increased in Massachusetts after the implementation of its landmark 2006 law requiring people to buy health insurance, a Harvard study says.
Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.
Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.
› Verified 3 days ago